|
gptkbp:instanceOf
|
gptkb:drug
stimulant
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06BA14
|
|
gptkbp:brand
|
gptkb:Sunosi
|
|
gptkbp:CASNumber
|
1010396-29-8
|
|
gptkbp:chemicalClass
|
phenylpropanolamine derivative
|
|
gptkbp:contraindication
|
concomitant use with MAO inhibitors
|
|
gptkbp:developer
|
gptkb:Jazz_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
7.1 hours
|
|
gptkbp:hasMolecularFormula
|
C10H15NO2
|
|
gptkbp:hasSMILES
|
CC(CC1=CC=CC=C1)NCC(=O)O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Solriamfetol
|
|
gptkbp:KEGGID
|
D10560
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine-norepinephrine reuptake inhibitor
|
|
gptkbp:molecularWeight
|
181.23 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
DB14761
CHEMBL2103887
23624651
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
anxiety
headache
insomnia
decreased appetite
|
|
gptkbp:UNII
|
6B1Y37R6NO
|
|
gptkbp:usedFor
|
treatment of narcolepsy
treatment of excessive daytime sleepiness
treatment of obstructive sleep apnea
|
|
gptkbp:bfsParent
|
gptkb:SK_Biopharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|